ClinicalTrials.gg
RecruitingNCT07477457Updated Mar 17, 2026

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

A Phase 2 interventional study of Methotrexate and Doxorubicin in Osteosarcoma and Metastasis, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 6 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
6 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Osteosarcoma by Memorial Sloan Kettering Cancer Center — 2 open to participants now, 4 under way, none of them phase 3. Osteosarcoma · Memorial Sloan Kettering Cancer Center.

Planned enrollment
5th of 10
45 · median 43
Started
2026
the only one that year
Phase 2
14 of 21
1 open now
Registered
21st of 21
by date

Among the 21 studies in Osteosarcoma by Memorial Sloan Kettering Cancer Center, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is one of 14 in phase 2, and was the 21st registered.

Osteosarcoma

488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.

Browse Osteosarcoma studies →

Open to participants now

2 of the 21 studies in Osteosarcoma by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.

This study: 6 Years to 49 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Osteosarcoma by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The researchers are doing this study to find out whether adding gefitinib, trametinib, disulfiram, and sunitinib to standard chemotherapy is a more effective treatment approach for people with osteosarcoma than standard chemotherapy on its own. The researchers will also look at the safety of adding these drugs to standard chemotherapy. The researchers will also use the additional research biopsies from Cohort 1 participants to learn more about how osteosarcoma survives during chemotherapy.

03

Conditions studied

  • Osteosarcoma
  • Metastasis

Keywords

  • Gefitinib
  • Trametinib
  • Disulfiram
  • Sunitinib
  • Metastatic Osteosarcoma
  • 25-257
04

Who can participate

Ages eligible
6 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cohort 1 only: Newly Diagnosed, Osteosarcoma

  1. For study entry, the suspected diagnosis of osteosarcoma may be based on clinical judgement. confirmation is required for treatment but as this protocol has biologic aims from serial tumor samples, some patients will be enrolled prior to open biopsy. Patients must have a histologic new diagnosis of metastatic high-risk osteosarcoma to start OstEvo systemic therapy. For purposes of this protocol, newly diagnosed, high-risk metastatic osteosarcoma includes:

    1. Having at least 1 extrapulmonary metastasis, radiographic confirmation of metastasis is adequate, and/or
    2. Unresectable metastases at diagnosis as determined by the investigator
  2. Patients may have started systemic conventional chemotherapy but must enroll on this study prior to day 29 of chemotherapy initiation. Having received a single standard MAP cycle (AP x 1 and HDMTX up to 2 times) of chemotherapy prior to enrollment is acceptable

Cohort 2 only: , Metastatic Osteosarcoma

1. Patients must have achieved a radiographically confirmed complete response as determined by the investigator from initial therapy and then relapsed with metastatic high-risk osteosarcoma. No strict size criteria of pulmonary or additional nodules for eligibility are required. For purposes of this protocol, relapsed, metastatic, high-risk osteosarcoma includes:

a. First relapse within 24 months of start of first chemotherapy or b. First relapse involving more than one lung nodule, or the lung and any extrapulmonary sites or c. First relapse with pleural disruption at relapse as determined by the investigator which can be determined by CT scan and/or d. Multiply relapsed patients are eligible provided the current relapse is in the context of a radiographically confirmed complete response on the scans preceding the relapse making them potentially eligible for OstEvo 2. Patients may have received only a single cycle of ifosfamide-containing conventional chemotherapy ever and included for the relapse making them eligible for OstEvo, but must enroll on this study prior to day 22 of the first cycle post-relapse

Cohort 3 only

  1. Patients with newly diagnosed osteosarcoma who are not eligible for Cohorts 1 or 2.
  2. Diagnostic biopsy has insufficient material for research.
  3. Must be enrolled on MSK IRB 12-245, biospecimen research protocol, with oncologic surgeries planned to be performed at MSK.
  4. Orthopedic surgeon assessment is that a research biopsy will not increase the risk of local recurrence.
  5. Patients must be willing to assent, and consenting party must consent to the single research biopsy prior to the initiation of chemotherapy. Patients over 18 must consent to research biopsies at study entry.

Cohorts 1 and 2 only

  1. Age: Patient must be > 6 and \< 50 years of age at the time of study enrollment.
  2. Disease Status: Metastatic high-risk osteosarcoma with cohort specific criteria above
  3. Performance Level: ≥ 50% for patients > 16 years of age and Lansky > 50 for patients \< 16 years of age within 28 days prior to enrollment.
  4. Oral Medications: Patients must be able to swallow oral medications as whole tablets/capsule form if a commercially available oral suspension is not available or if tablet dissolution is not stated in the protocol.
  5. Organ Function Requirements:

    1. Adequate Hematologic function, defined as:

    i. > 250 cells/mcL ii. count > 50,000/mcL b. Adequate Renal Function, defined as: i. May use (estimated or by cystatin C) or radioisotope > 70 mL/min/1.73m2 or estimated GFR (eGFR) in pediatric patients ii. A serum creatinine based on age/sex (use the Schwartz formula for estimating GFR) c. Adequate Liver Function, defined as: i. Total \< 1.5 x for age ii. and ALT \< 3 x ULN for age d. Adequate Cardiac Function, defined as: i. No history of congenital prolonged syndrome ii. Correct QT (using Fridericia's correction [QTcF]) interval \< 480 msec.

1. QTcF = QT / RR(0.33), where RR = 60 / heart rate in bpm iii. (LVEF) > 55 % on echocardiogram or MUGA 6. Assent and Consent: Patients at least 7 years old and less than 18 years old must be willing to assent, and consenting party must consent to research biopsies in Cohort 1. Patients 18 years and older must consent to research biopsies at study entry. All patients and/or their parents or legal guardians must have the ability to understand and the willingness to sign a written or assent document.

7. Tumor Tissue: Patients must have adequate biopsy tumor tissue, or the patient is willing to undergo a pretreatment research biopsy. A research biopsy following cycles 1 and 2 of treatment done with the thoracotomy procedure will be required. Availability of these paired biopsies will be informative to understanding mechanisms of response and resistance to initial therapy in osteosarcoma and may benefit future patients with this rare cancer.

8. Concurrent Study Enrollment: Must be enrolled on MSK IRB 12-245, biospecimen research protocol, with oncologic surgeries planned to be performed at MSK.

9. Pregnancy or Breast Feeding: The effects of the chemotherapeutic agents in OstEvo on the developing human fetus are unknown. For this reason and because OstEvo agents as well as other therapeutic agents used in this trial are known to be teratogenic, participants of must agree to use adequate (hormonal or barrier method of birth control; abstinence) during study therapy and for 12 months following the completion of study therapy. Should a participant become pregnant or suspect pregnancy while participating in this study, they should inform their treating physician immediately.

10. Contraception: Women of childbearing potential should adhere to contraception from enrollment through 12 months after completion of systemic chemotherapy administration. Men who are sexually active with women of childbearing potential should adhere to contraception from enrollment through 12 months after completion- of systemic chemotherapy administration 11. Protocol Adherence: Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and evaluations.

Exclusion criteria

Exclusion Criteria:

Cohorts 1 and 2 only:

  1. Patients who are receiving any other agents for osteosarcoma therapy are ineligible.
  2. Patient with an uncontrolled chronic or active infection or another condition where any component of OstEvo therapy would be .
  3. Patients with a history of heart disease including, but not limited to: uncontrolled hypertension within 12 months prior to enrollment; ongoing cardiac dysrhythmias ≥ grade 2 or atrial fibrillation of any grade; unstable angina, symptomatic congestive heart failure, or prior myocardial infarction.
  4. Patients must not be receiving any additional medicines being given for the specific purpose of treating cancer. Alternative medications including, but not limited to cannabis-based products would not be a reason for exclusion.
  5. Patients with any medical or surgical conditions that would interfere with gastrointestinal absorption of oral agents.
  6. Patients may not have received prior cardiac irradiation.

Cohort 2 only:

5. Patients must not have previously been enrolled in OstEvo

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Newly Diagnosed, Metastatic Osteosarcoma

    Patient will receive study treatment that includes standard MAP chemotherapy in addition to either gefitinib, trametinib, disulfiram, or sunitinib, or a combination of some of these drugs. Participants will receive the study treatment during 6 treatment Cycles. Each Cycle will last 28 days.

    Drug: Methotrexate · Drug: Doxorubicin · Drug: Cisplatin · Drug: Gefitinib · Drug: Trametinib · Drug: Disulfiram · Drug: Sunitinib

  • Experimental
    Relapsed, Metastatic Osteosarcoma

    Patient will receive study treatment that includes standard ifosfamide chemotherapy in addition to either gefitinib, trametinib, disulfiram, or sunitinib, or a combination of some of these drugs. Participants will receive the study treatment during 6 treatment Cycles. Each Cycle will last 21 days.

    Drug: Gefitinib · Drug: Trametinib · Drug: Disulfiram · Drug: Sunitinib · Drug: Ifosfamide

  • Experimental
    Newly Diagnosed Osteosarcoma

    Research Biopsy only

    Procedure: Biopsy

Interventions

  • Methotrexate 12 g/m\^2 (max dose 20 grams) intravenously over 4 hours or as per institutional standard.

  • Doxorubicin 37.5 mg/m\^2 intravenously over 15 to 30 minutes or as per institutional standard.

  • Cisplatin 60 mg/m\^2 intravenously over 4 hours or as per institutional standard.

  • Gefitinib 400 mg/m\^2/dose (maximum dose 250 mg) orally daily for 14 days (14 doses)

  • Trametinib will be dispensed as per institutional standard.

  • Disulfiram 250 to 500 mg orally once daily for 14 days

  • Sunitinib capsules for under 18 years of age: 15 mg/m\^2/dose (maximum 50 mg) orally once daily x 14 days

  • Ifosfamide 2,800 mg/m\^2 intravenously as per institutional standard.

  • ProcedureBiopsy

    Research biopsy prior to therapy

06

What researchers measure

Primary outcomes

  1. 12-month progression free survival (PFS) (cohort 1)

    Response will be determined by the investigator and progression will be guided by RECIST 1.1 criteria

    Time frame: 12 months

  2. 24-month overall survival (OS) (cohort 2)

    Response will be determined by the investigator and progression will be guided by RECIST 1.1 criteria

    Time frame: 24 months

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Damon Reed, MD · Contact1-833-MSK-KIDS
  • Memorial Sloan Kettering at Monmouth (Limited Protocol Activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Damon Reed, MD · Contact1-833-MSK-KIDS
  • Memorial Sloan Kettering at Bergen (Limited Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Damon Reed, MD · Contact1-833-MSK-KIDS
  • Memorial Sloan Kettering at Suffolk-Commack (Limited Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Damon Reed, MD · Contact1-833-MSK-KIDS
  • Memorial Sloan Kettering at Westchester (Limited Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • Damon Reed, MD · Contact1-833-MSK-KIDS
  • Memorial Sloan Kettering Cancer Center (All Protocol Activites)
    New York, New York 10065, United States
    Recruiting
    • Damon Reed, MD · Contact1-833-MSK-KIDS
  • Memorial Sloan Kettering at Nassau (Limited Protocol Activities)
    Uniondale, New York 11553, United States
    Recruiting
    • Damon Reed, MD · Contact1-833-MSK-KIDS
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.

Of 72 non-industry phase 2 interventional studies under Osteosarcoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's planned 24 months is below that.

Counting every sponsor, half of 76 studies reached it within 65 months; a quarter within 40 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 17, 2026
StartActual
Mar 11, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Mar 11, 2028
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07477457
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Mar 11, 2026
Primary completion
Mar 2028 (estimated)
Completion
Mar 11, 2028 (estimated)
Last update
Mar 17, 2026

Study contacts

Damon Reed, MD
Contact
reedd1@mskcc.org
1-833-MSK-KIDS
Asmin Tulpule, MD, PhD
Contact
1-833-MSK-KIDS
Damon Reed, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gefitinib · Trametinib · Disulfiram · Sunitinib

Start the discussion